Market Forecast By Product (Polysaccharide, Conjugate), By Age Group (Infants, Children, Adolescents & Young Adults, Adults), By Distribution Channel (Pharmacies, Community Clinics, Public Health Agencies, Others) And Competitive Landscape
Product Code: ETC332675 | Publication Date: Aug 2022 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Report Name | Australia Meningococcal Vaccines Market |
Forecast period | 2025-2031 |
CAGR | 10.4% |
Growing Sector | Healthcare |
The Australia Meningococcal Vaccines Market report thoroughly covers the market by product, by age group, and by distribution channel. The market report provides an unbiased and detailed analysis of the ongoing market trends, opportunities/high growth areas, and market drivers which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.
Australia Meningococcal Vaccines Market has accomplished major success and is projected to attain more in the coming years on the back of the increasing awareness about vaccine-preventable diseases, government initiatives for immunization programs, and advancements in technology. The market is also going through certain challenges that can hamper its growth to a certain extent in the near future.
According to 6Wresearch, the Australia Meningococcal Vaccines Services Market size is expected to grow at a CAGR of 10.4% during 2025-2031. Meningitis causes fatal tissue inflammation surrounding the brain and spinal cord and is majorly caused by several species of bacteria, viruses, fungi, and parasites. One of the major drivers for the growth of the market is the increasing awareness of diseases and their consequences. People have better access to media and healthcare providers, becoming more aware of meningitis and taking preventive measures by being vaccinated.
The government’s efforts to control meningococcal disease are another driver that contributes to the growth of the market. Several states in Australia have implemented vaccination programs targeting school-aged children and young adults, which has significantly increased the demand for meningococcal vaccines. However, despite growth and demand in the market, there are some challenges faced by the Australia Meningococcal Vaccines market that hinder the growth of the market. One of the main challenges is the high cost of meningococcal vaccines. This makes it difficult for low-income families to afford and get immunized by being vaccinated. The limited availability of meningococcal vaccine brands in Australia is the other restraint that is hampering the growth of the market. This can be due to disruptions in the supply chain or regulatory barriers, which may limit the options available for healthcare providers and patients.
Some of the key players in the Australia Meningococcal Vaccines Market include Australia Meningococcal Vacciness GlaxoSmithKline (GSK), Pfizer Inc., Sanofi Pasteur, Merck & Co. Inc., and Novartis AG. Moreover, these firms hold enormous Name Market Revenues. Further, the Australian meningococcal vaccine market is dominated by major global players who are constantly investing in research and development to provide high-quality vaccines for consumers. As new strains of meningococcal bacteria emerge and the demand for vaccines increases, these companies will continue to play a crucial role in providing effective prevention against this deadly disease.
The government has recognized the threat of meningococcal disease and has taken several initiatives to prevent it and increase awareness and availability of vaccines in the market. The government has announced a new policy, that provides free meningococcal ACWY vaccines to children aged 14 to 19 years through schools and community health clinics. Furthermore, the government has also implemented a National Immunization Program to provide free vaccinations for children and adolescents, including meningococcal vaccines, which aims to increase national immunization rates and reduce the burden of vaccine-preventable diseases in Australia. Further, these plans have improved the Name Market Share. Moreover, the Australian government is working with healthcare working professionals and organizations to boost and promote the importance of meningococcal vaccines. In addition, the government has also invested in research and development for new and improved meningococcal vaccines.
The Australia Meningococcal Vaccines Market is witnessing significant growth in the future driven by increasing awareness about vaccine-preventable diseases, government initiatives for immunization programs, and advancements in technology. With continued efforts from various stakeholders, it is expected that cases of meningococcal disease will decrease, and more individuals will have access to lifesaving vaccines.
According to Ravi Bhandari, Research Manager, 6Wresearch, the infants segment dominated this industry. The segment will grow in the coming years as infants are at a higher risk of contracting meningococcal diseases, and therefore, vaccination at an early age is crucial.
In terms of Distribution Channel, the hospitals and clinics segment dominated this industry. The segment will grow in the coming years due to efficient cold chain infrastructure and trained medical staff, hospitals and clinics are able to provide timely immunization services to patients.
The report offers a comprehensive study of the subsequent market segments:
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Meningococcal Vaccines Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Meningococcal Vaccines Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Meningococcal Vaccines Market - Industry Life Cycle |
3.4 Australia Meningococcal Vaccines Market - Porter's Five Forces |
3.5 Australia Meningococcal Vaccines Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.6 Australia Meningococcal Vaccines Market Revenues & Volume Share, By Age Group, 2021 & 2031F |
3.7 Australia Meningococcal Vaccines Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Meningococcal Vaccines Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the importance of vaccination in preventing meningococcal disease |
4.2.2 Growing government initiatives to include meningococcal vaccines in national immunization programs |
4.2.3 Rising incidences of meningococcal disease in Australia |
4.3 Market Restraints |
4.3.1 High cost associated with meningococcal vaccines |
4.3.2 Limited access to vaccines in rural and remote areas of Australia |
4.3.3 Potential side effects or concerns about vaccine safety |
5 Australia Meningococcal Vaccines Market Trends |
6 Australia Meningococcal Vaccines Market, By Types |
6.1 Australia Meningococcal Vaccines Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 Australia Meningococcal Vaccines Market Revenues & Volume, By Product, 2021-2031F |
6.1.3 Australia Meningococcal Vaccines Market Revenues & Volume, By Polysaccharide, 2021-2031F |
6.1.4 Australia Meningococcal Vaccines Market Revenues & Volume, By Conjugate, 2021-2031F |
6.2 Australia Meningococcal Vaccines Market, By Age Group |
6.2.1 Overview and Analysis |
6.2.2 Australia Meningococcal Vaccines Market Revenues & Volume, By Infants, 2021-2031F |
6.2.3 Australia Meningococcal Vaccines Market Revenues & Volume, By Children, 2021-2031F |
6.2.4 Australia Meningococcal Vaccines Market Revenues & Volume, By Adolescents & Young Adults, 2021-2031F |
6.2.5 Australia Meningococcal Vaccines Market Revenues & Volume, By Adults, 2021-2031F |
6.3 Australia Meningococcal Vaccines Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Australia Meningococcal Vaccines Market Revenues & Volume, By Pharmacies, 2021-2031F |
6.3.3 Australia Meningococcal Vaccines Market Revenues & Volume, By Community Clinics, 2021-2031F |
6.3.4 Australia Meningococcal Vaccines Market Revenues & Volume, By Public Health Agencies, 2021-2031F |
6.3.5 Australia Meningococcal Vaccines Market Revenues & Volume, By Others, 2021-2031F |
7 Australia Meningococcal Vaccines Market Import-Export Trade Statistics |
7.1 Australia Meningococcal Vaccines Market Export to Major Countries |
7.2 Australia Meningococcal Vaccines Market Imports from Major Countries |
8 Australia Meningococcal Vaccines Market Key Performance Indicators |
8.1 Percentage increase in vaccination coverage rates for meningococcal vaccines |
8.2 Number of government-funded vaccination campaigns targeting meningococcal disease |
8.3 Research and development investments in new and improved meningococcal vaccine formulations. |
9 Australia Meningococcal Vaccines Market - Opportunity Assessment |
9.1 Australia Meningococcal Vaccines Market Opportunity Assessment, By Product, 2021 & 2031F |
9.2 Australia Meningococcal Vaccines Market Opportunity Assessment, By Age Group, 2021 & 2031F |
9.3 Australia Meningococcal Vaccines Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Meningococcal Vaccines Market - Competitive Landscape |
10.1 Australia Meningococcal Vaccines Market Revenue Share, By Companies, 2024 |
10.2 Australia Meningococcal Vaccines Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |